End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
173,800 KRW | -1.70% | -3.50% | -13.75% |
06-17 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
06-14 | Celltrion, Inc. announces an Equity Buyback for 410,734 shares. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.75% | 25.8B | |
+21.85% | 46.44B | |
+37.63% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B | |
-8.20% | 9.12B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug